SLC1A2 and Alzheimer disease: GLT-1 dysfunction exacerbates cognitive deficits and accelerates disease progression in AD animal models [30,31], influencing Aβ metabolism and glutamatergic signaling pathways critical to AD pathogenesis [32,33,34,35,36].